Novel combination therapies for the treatment of cancer and inflammation
Combination therapies for the treatment of cancer and inflammation and a genetic screen for the identification of further synergistic combinations.
Oncology and inflammation
Innovations and Advantages
Using a novel genetic screen, the laboratory of Fritz Roth has demonstrated that certain known compounds, with a demonstrated safety and pharmacological profile, can be enhanced by administration of another, non-obvious compound. By co-administering these synergistic combinations, increased efficacy and a reduction in dosing levels is made possible.
Synergistic effects were demonstrated in non-steroidal, immuniphilin-dependent immunosuppressants, including cyclosporine, tacrolimus, and rapamycin. Co-administration of these compounds with other known and safe compounds exhibited unexpected synergism in the prevention of proliferation. Likewise, similar results were shown in different compounds with anti-fungal applications.
Intellectual Property Status: Patent(s) pending
Chua, Hon Nian
Roth, Frederick P.
For further information, please contact:
Grant Zimmermann, Director of Business Development
Reference Harvard Case #3569